SELLAS Life Sciences Group, Inc. (SLS)
Health Care ยท Pharmaceutical Preparations
SELLAS Life Sciences Group, Inc. (SLS) is listed on Nasdaq, where its shares have traded since March 12, 2008. SentiSense covers SELLAS Life Sciences Group, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Angelos M. Stergiou is its chief executive officer. The company reports 13 employees, and its corporate website is www.sellaslifesciences.com.
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Latest reported results
SELLAS Life Sciences Group, Inc. reported revenue of $0.00 for Q3 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 184 institutions reported holding SLS, with 73.6 million shares worth $1.1 billion in aggregate. The largest reported holders were BlackRock, State Street and Vanguard. Of the 5 largest reported holders, 1 opened a new position in SLS and 4 added shares during the quarter.
More on SLS
- SLS sentiment: whether news and social coverage of SELLAS Life Sciences Group, Inc. leans bullish or bearish, and the stories driving it.
- SLS ownership: all 184 reporting institutions, plus insider and congressional trades.
- SLS financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for SELLAS Life Sciences Group, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does SELLAS Life Sciences Group, Inc. do?
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.
What sector is SLS in?
SentiSense classifies SELLAS Life Sciences Group, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does SLS stock trade?
SELLAS Life Sciences Group, Inc. (SLS) is listed on Nasdaq, where its shares have traded since March 12, 2008.
Who is the CEO of SELLAS Life Sciences Group, Inc.?
Angelos M. Stergiou is the chief executive officer of SELLAS Life Sciences Group, Inc..